Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Uveal melanoma has long lagged behind skin melanoma in treatment options, but a wave of targeted and T-cell–based therapies is changing that. From a drug combo outperforming immunotherapy in HLA-negative patients to a promising TCR bispecific duo, plus a precision biomarker guiding TIL therapy selection, the field is seeing meaningful progress. Experts say patients can now realistically expect to live significantly longer than the previous grim prognosis suggested.
Uveal melanoma — a rare eye cancer that spreads most often to the liver — has historically been resistant to the immunotherapies that transformed outcomes in skin melanoma. But data from the 2026 ASCO and SITC Annual Meetings signal a turning point, with multiple targeted and cell-based approaches showing real promise.
For patients who lack the HLA-A*02:01 marker (making them ineligible for the only FDA-approved agent, tebentafusp), the oral combo of darovasertib + crizotinib delivered a median progression-free survival of 6.9 months vs. just 3.1 months with standard immunotherapy in the phase 2/3 OptimUM-02 trial. Meanwhile, for HLA-positive patients, combining tebentafusp with the PRAME-targeting agent brenetafusp yielded a 29% response rate and an estimated 2-year overall survival of 70% in early-phase data. A separate trial found that tumor-reactive TIL therapy achieved a 37–43% response rate — but only when guided by a novel biomarker called UMIS, which predicted TIL reactivity far better than tumor mutational burden.
Key Takeaways:
Why it matters: These advances collectively suggest that patients with metastatic uveal melanoma — once facing a prognosis of just a few months — may now have a realistic path to long-term survival with the right therapy matched to their biology.